



# Working together to uniformly license veterinary medicines in East Africa: How the East African Community's Mutual Recognition Procedure works

2nd edition

East African Community, December 2021



# Contents

<b>1</b>	<b>Introduction</b>	<b>3</b>
<b>2</b>	<b>The Principle of MRP</b>	<b>4</b>
<b>3</b>	<b>When to Use MRP</b>	<b>5</b>
<b>4</b>	<b>Eligibility for MRP</b>	<b>5</b>
<b>5</b>	<b>Time-keeping and Co-ordination</b>	<b>6</b>
<b>6</b>	<b>Ability of Partner States to participate in MRP</b>	<b>6</b>
<b>7</b>	<b>Guidance and Rules for MRP</b>	<b>6</b>
<b>8</b>	<b>GMP Inspections</b>	<b>6</b>
<b>9</b>	<b>Post MRP</b>	<b>7</b>
<b>10</b>	<b>Fees</b>	<b>7</b>
<b>11</b>	<b>Summary Timeline of the Mutual Recognition Procedure (MRP)</b>	<b>8</b>
<b>12</b>	<b>Detailed Timeline of the Mutual Recognition Procedure (MRP)</b>	<b>9</b>
<b>13</b>	<b>MRP Chart</b>	<b>10</b>
<b>14</b>	<b>References</b>	<b>12</b>
<b>15</b>	<b>Acknowledgements</b>	<b>12</b>

# Abbreviations

<b>CC</b>	Concerned Country
<b>CGMR</b>	Coordination Group for Mutual Recognition
<b>EAC</b>	East African Community
<b>EU</b>	European Union
<b>GALVmed</b>	Global Alliance for Livestock Veterinary Medicines
<b>GMP</b>	Good Manufacturing Practice
<b>IVP</b>	Immunological Veterinary Product
<b>MA</b>	Marketing Authorisation
<b>MR-C</b>	Mutual Recognition Coordinator
<b>MRP</b>	Mutual Recognition Procedure
<b>NRA</b>	National Regulatory Authority
<b>OIE</b>	World Organisation for Animal Health
<b>RC</b>	Reference Country
<b>TWG</b>	Technical Working Group

# 1 Introduction

---

Most countries in the world have a system of assessment and approval of medicines to ensure that they meet high standards of safety, quality and efficacy before they are authorised for sale. This process is often called registration. It results in the issue of a licence or Marketing Authorisation (MA) granted by the national regulatory authority to the applicant/manufacturer of the product. Similar systems exist for both human and veterinary medicines.

In some countries there are no systems in place for registering medicines, whilst in countries that do have a registration system it is often designed for human medicines with no distinction being made between requirements for pharmaceuticals and vaccines. Assessing applications under these circumstances, without clear, specific guidelines can lead to long delays for applicants seeking MAs. Dossiers sent to several countries are assessed at different speeds with each country sending its own unique set of questions back to the applicant for their responses.

The international not-for-profit company, the Global Alliance for Livestock Veterinary Medicines (GALVmed), works with the animal health sector in the East African region. Through its work, the company noticed the varying challenges surrounding the different veterinary registration systems throughout Africa. These were discussed in a 2010 OIE conference workshop that GALVmed ran on the subject. The outcome of that conference was that many African countries asked GALVmed to provide training for their regulators in appropriate assessment of veterinary vaccine applications and a Mutual Recognition Procedure (MRP) to avoid duplication of assessments of the same product by different regulatory authorities.

The first step in developing an MRP is to ensure that each one of a group of countries is working to the same standards. This can be achieved by developing harmonised guidelines, which each of the countries agrees to follow.

In 2012, representatives from the national regulatory authorities (NRAs) in the East African region formed an interim Technical Working Group (TWG). The group successfully developed a harmonised process for the registration of veterinary vaccines, referred to as Immunological Veterinary Products (IVPs), with technical and financial support from GALVmed.

The outcome was a series of technical documents including:

- A guideline explaining the information that should be included in the dossier<sup>1</sup>;
- A guideline explaining the structure of the registration dossier<sup>2</sup>;
- Templates for the details to be included on the packaging of the product<sup>3</sup>;
- A harmonised application form for applicants to complete<sup>4</sup>.

As a result of developing this harmonised system, GALVmed was able to recommend an MRP for regulators to use within the EAC, which would also be incorporated into their own national systems.

This is explained in section 2.

The MRP could be used for both veterinary immunologicals and veterinary pharmaceuticals. The veterinary immunological and veterinary pharmaceutical registration requirements have been harmonised to date.

<sup>1</sup> Guideline on the technical documentation required to be included in a Registration Dossier for an Immunological Veterinary Product/Veterinary Pharmaceutical Product. See GL2 & GL 13 at: <https://www.eac.int/documents/category/livestock>

<sup>2</sup> Registration Dossier Structure for an Immunological Veterinary Product. See GL1 at: <https://www.eac.int/documents/category/livestock>

<sup>3</sup> Templates for the Summary of Product Characteristics and Packaging for an Immunological Veterinary Product. See T1 at: <https://www.eac.int/documents/category/livestock>

<sup>4</sup> EAC Application Form. See F1 at: <https://www.eac.int/documents/category/livestock>

## 2 The Principle of MRP


---

This MRP was developed to reduce duplication of assessments and site inspections for the same medicinal product throughout the regional economic community. It will also help towards building experience, confidence, and trust between the regulators in each Partner State in the EAC. The principle of MRP is that only one National Regulatory Authority (NRA), known as the Reference Country (RC) performs the assessment of the registration dossier and application. The dossier contains administrative information on the product, including:

- A Summary of Product Characteristics and Labelling text in the first section,
- Detailed information on Production and Quality Control of the product in the second section.
- Reports of clinical data to demonstrate that the product is safe and efficacious in the last two sections.

After the dossier is reviewed, the RC prepares an assessment report, which is then shared with all the NRAs of the participating Partner States where the applicant has chosen to market the product. These Partner States are known as the Concerned Countries (CCs).

MRP is particularly valuable for manufacturers of veterinary vaccines, which is why the system has been introduced for them first. Some regions of the world, e.g., the European Union (EU), offer a centralised registration system where applicants apply for an MA that, if successful, is valid in all 28 Member States of the EU. The process is extremely expensive for applicants; however, it allows them access to 28 markets. In contrast, a veterinary vaccine – e.g., a vaccine for a species of farmed fish – may only have markets in two or three countries depending on the need for the vaccine in each country. The MRP allows the applicant to register their vaccine/medicines in those particular countries promptly and simultaneously.



## 3 When to use MRP

---

The MRP system may be used in the following cases:

- 1 New Licences (MAs):** When an applicant wishes to obtain MAs for a new product in several Partner States simultaneously.
- 2 Extending a Current Licence (MA) to another EAC Country:** When an applicant already has an MA in one Partner State and wishes to have this mutually recognised to expand sales into one or more additional Partner States.

However, should the applicant only want an MA in one Partner State, National MAs may still be issued by NRAs. Whenever an applicant seeks more than one MA for the same product in EAC Partner States they must apply for MAs through MRP. The MAs issued by the RC and CCs are all national MAs that are allocated their MA numbers according to the national processes. However, products registered through MRP will also be uploaded on the EAC livestock website. These numbers identify the product as one that has been registered through MRP and that will continue to be administered as a MRP product through the harmonised process.

## 4 Eligibility for MRP

---

### New MAs:

The applicant prepares a registration dossier according to the format and guidelines published on the EAC and NRA's websites.

The applicant contacts their proposed RC to ask them to act as their RC in an MRP. The applicant may request a Pre-submission meeting with the RC. A guideline for this is available<sup>5</sup>.

The RC will advise the applicant if their dossier meets the EAC requirements and is eligible for MRP.

### Extending Current MAs into other EAC Countries:

The applicant approaches one of the NRAs where the MA is already granted. This NRA becomes the RC. The applicant sends their dossier to the RC who advises them whether or not the dossier should be revised to bring it in line with current requirements. Once the RC is satisfied that the application is eligible for MRP the process begins as described in section 11.

<sup>5</sup> Guideline for a Pre-Submission meeting. See GL6 at: <https://www.eac.int/documents/category/livestock>

## 5 Timekeeping and Co-ordination

---

The MRP is run against a clock to ensure a smooth, transparent and efficient process. To co-ordinate this, each Partner State nominates a representative to the Coordination Group for Mutual Recognition (CGMR). They may also nominate a deputy CGMR member. The CGMR members are the links between their NRAs and a Mutual Recognition Coordinator (MR-C).

The MR-C is responsible for ensuring that the MRP remains on track. The MR-C is the link between the RC and the CCs, via the members of the CGMR and the EAC Secretariat.

Once the RC agrees that an application is eligible for MRP, they inform the MR-C who works out the timetable for the MRP. The MR-C sends the RC and the CGMR members the calendar dates for the critical days of MRP, e.g. Day 90, Day 120, Day 160, etc. Once the MRP has begun, the CGMR members are responsible for communicating the opinions of their NRAs to the MR-C by the calendar dates established by the MR-C's timeline. The MR-C advises the RC, CGMR members and the EAC on the progress of each MRP and ensures that it is completed by the relevant date.

## 6 Ability of partner states to participate in MRP

---

At any given time, not all of the EAC Partner States may be able to participate in MRPs, especially new Partner States that do not yet have a functioning Regulatory Authority. The RC will be able to advise applicants about this.

## 7 Guidance and Rules for MRP

---

Guidance for applicants wishing to use MRP is available in the form of a Best Practice Guide<sup>6</sup>, which will be published on the EAC website: [www.eac.int](https://www.eac.int/documents/category/livestock) with <https://www.eac.int/documents/category/livestock>. **GL5** This BPG contains a set of rules that must be followed in all MRPs.

## 8 GMP inspections

---

The RC will advise the applicant if and when a GMP inspection will take place. The RC/CC will arrange for the GMP inspection to be completed during the assessment phase of the MRP.

<sup>6</sup> Best Practice Guide for Mutual Recognition Procedures. See GL5 at: <https://www.eac.int/documents/category/livestock>

## 9 Post MRP

---

Once a veterinary medicinal product has been recommended for approval the process is taken over by the participating states for issuance of MAs.

- The renewal period of 5 years after the first registration will be the responsibility of individual Nation Regulatory Authorities.
- Any variations that the applicant subsequently applies for are processed through the original RC and, if successful, are approved simultaneously in the RC and CCs

## 10 Fees

---

Registration fees payable to the RC and the CCs will be the same as the current fees published by the respective Partner States. They can be found on the respective NRAs' websites. Some NRAs may decide to charge an additional fee for acting as the RC. This will be indicated on their websites.



# 11 Summary timeline of the mutual recognition procedure (MRP)

Before this MRP was introduced, applicants wishing to register veterinary vaccines/medicines had to apply separately to each NRA for authorisation to sell the product in that country. The time between submitting the application and obtaining an MA varied in each country from two to six years and progress was usually unpredictable.

The new harmonised MRP offers a rapid, efficient and predictable system for applicants. Below is a summary timeline of this process. See section 12 below for a detailed description of the procedure.

## SUMMARY MRP TIMELINE

- i. The applicant selects which NRA they want to run the MRP.
  - That NRA is the RC.
- ii. The applicant also chooses the other Partner States where they want to market the product.
  - These NRAs are the CCs.
- iii. Once the applicant has been advised that their application is eligible for MRP (see section 6 below) they send the registration dossier, application form and fees to the RC and CCs simultaneously.
- iv. The RC and CCs have 7 days to confirm that they have received a valid application.
- v. From the point of the application confirmation, the processing clock starts:
  - **Days 0 – 90:** The RC has 90 days to write an Assessment Report of the dossier and then sends their Assessment Report to each of the CCs.
  - **Days 90 – 120:** The CCs have 30 days to review the Assessment Report and decide if they agree that it shows that the product is safe, efficacious and of good quality.
- vi. Depending on the outcome of that review, three different timelines are available for completion of the process:

## SCENARIO 1: SHORT PROCESSING TIME

- **Days 120:** If no queries are raised and the applicant has a valid GMP certificate. The RC and CCs by Day 120 confirm recommendation of the product, MAs are issued by Day 210.

## SCENARIO 2: MEDIUM PROCESSING TIME

- **Days 120 – 280:** If the CCs raises questions for the applicant and the RC and CC don't agree to drop the question the applicant is asked to respond to the questions by Day 160. The RC and CC evaluate the responses and agree it is satisfactory by Day 190. If successful, it ends with MAs being issued by Day 280.

## SCENARIO 3: EXTENDED PROCESSING TIME

- **a) Days 120 – 300:** If the RC and CCs raised questions. The RC takes 10 days to collate the questions and sends them to applicant by day 130
- **Between Day 130 and Day 160:** The Applicant sends their responses to the consolidated list of questions to the RC. The RC evaluates the responses to the consolidated list of questions provided by the applicant by Day 190. The RC then sends the evaluation report to the CC, copying the MRC. If RC evaluation report is positive and the CCs agree with it by day 210 then the clock stops.
- If the RC and CC are not able to agree and the area of concerns remain, the RC requests the applicant to provide additional clarification to the questions by day 240. Once the applicant provides satisfactory responses, the CLOCK STOPS at day 240.

*For a visual representation of these timelines, please see the graphs on pages 10 and 11.*

# 12 Detailed timeline of the mutual recognition procedure (MRP)

---

## SCENARIO 1:

### SHORT PROCESSING TIME

- **Days 0 – 90:** For each type of MRP, the RC may ask the applicant for clarification on anything included in the dossier during this time. The applicant provides their responses to the RC who ensures that the responses are reflected in the assessment report. The assessment report is sent to the CCs for review.
- **Days 90 – 120:** If the CCs do not raise any questions by Day 120, the clock stops, and the MAs are issued by the RC and CCs within 90 days.
- **Day 210:** MAs are issued.

## SCENARIO 2:

### MEDIUM PROCESSING TIME

- **Days 90 – 120:** The CCs raises a concern on the assessment report from the RC, and the RC and CC have twenty days to agree and to settle the area of concern. If they don't agree the applicant is requested to respond to the question.
- **Day 170:** The applicant sends their responses to the RC, who shares them with the CCs.
- **Day 190:** The RC and CCs decide that the responses are suitable and that an MA can be granted. The applicant is asked to send their revised Summary of Product Characteristics and labelling text to the RC and CCs for review.
- **Day 190:** The MRP processing clock stops.
- **Day 280:** MAs issued by RC and CCs.

## SCENARIO 3:

### EXTENDED PROCESSING TIME

- **Days 0 – 190:** See Scenario 2 above.
- **Day 0 – 120:** If the RC and CCs raises questions. The RC takes 10 days to collate the questions and sends to applicant by day 130
- Between Day 130 and Day 160 the Applicant sends their responses to the consolidated list of questions to the RC. The RC evaluates the responses to the consolidated list of questions provided by the applicant by Day 190. The RC then sends the evaluation report to the CC, copying the MRC. If RC evaluation report is positive and the CCs agree with it by day 210 then the clock stops (**Scenario 3a**).
- If the RC and CC are not able to agree and the concerns remain, the RC requests the applicant to provide additional clarification to the questions by day 240. Once the applicant provides satisfactory responses, the CLOCK STOPS at day 240, (**Scenario 3b**). See Scenario 3a or 3b for the relevant end of this process.

### SCENARIO 3a:

- **Days 200 – 210:** If a positive decision (for negative decision go to Scenario 3b)
- **Days 210:** RC and CCs confirm approval.
- **Days 300:** The MAs are issued.

### SCENARIO 3b:

- **Days 240:** If a positive decision (for negative decision go to Scenario 3b)
- **Days 240:** RC and CCs confirm approval.
- **Days 330:** The MAs are issued.

*For a visual representation of these timelines, please see the graphs on pages 10 and 11.*

# 13 MRP Chart




## Mutual Recognition Procedure for Veterinary Vaccines in the EAC

Short and Medium Processing Times (120 - 280 days)



Application process begins here






# Mutual Recognition Procedure for Veterinary Vaccines in the EAC

Extended Processing Times (210 – 330 days)



## Application process begins here



# 14 References

---

- 1 Guideline on the technical documentation required to be included in a Registration Dossier for an Immunological Veterinary Product and Pharmaceutical products. See GL2 & GL13 at:  
<https://www.eac.int/documents/category/livestock>
- 2 Registration Dossier Structure for an Immunological Veterinary Product. See GL1 at:  
<https://www.eac.int/documents/category/livestock>
- 3 Templates for the Summary of Product Characteristics and Packaging for an Immunological Veterinary Product. See T1 at:  
<https://www.eac.int/documents/category/livestock>
- 4 EAC Application Form. See F1 at:  
<https://www.eac.int/documents/category/livestock>
- 5 Guideline for a Pre-Submission meeting. See GL6 at:  
<https://www.eac.int/documents/category/livestock>
- 6 Best Practice Guide for Mutual Recognition Procedures. See GL5 at:  
<https://www.eac.int/documents/category/livestock>

# 15 Acknowledgements

---

The EAC appreciates the technical and financial support received from GALVmed in the development of these guidelines. The community would also like to thank in particular, the EAC Technical Working Group, EAC Secretariat as well as Gilly Cowan, GALVmed's Regulatory Affairs Consultant, who has been instrumental in the development of this document and Heather Irish, GALVmed's Communications Officer, who edited this work.

GALVmed is funded by the Bill & Melinda Gates Foundation and the UK Government. The views expressed in this document are those of the author and do not necessarily represent the views of the Bill & Melinda Gates Foundation nor the UK Government.

*Updated November 2021*





EAC Close, Afrika Mashariki Road  
P.O. Box 1096  
Arusha  
United Republic of Tanzania

Tel +255 (0)27 216 2100

Fax +255 (0)27 216 2190

<http://www.eac.int/>

 @jumuiya

BILL & MELINDA  
GATES *foundation*



This work was funded by GALVmed, which receives funding from the Bill & Melinda Gates Foundation and the UK Government. The views expressed in this document are those of the author and do not necessarily represent the views of the Bill & Melinda Gates Foundation nor the UK Government.

Photo credits: Front cover - Daniel Naude; Inside pages: GALVmed/Karel Prinsloo